Mount Sinai Receives $2.9 Million to Study First-of-its-kind Brain Implant for Restoring Function in Paralyzed Patients
Department of Rehabilitation and Human Performance will lead Mount Sinai in national clinical trial
Mount Sinai researchers have received $2.9 million from the National Institutes of Health to study whether a first-of-its-kind brain implant can improve the ability of severely paralyzed patients to communicate. The grant is part of a $10 million award that will fund a national multi-center clinical trial that will be first to implant this device and study it in United States patients. Its findings could lead to a new therapy for this population, giving them independence to perform basic, important tasks and improve their quality of life.
“This will be an historic clinical trial that has the potential to change what is possible for people living with severe paralysis,” says David Putrino, PhD, PT, Director of Rehabilitation Innovation for the Mount Sinai Health System and a Principal Investigator of the study. “We are excited that Mount Sinai’s Department of Rehabilitation and Human Performance and Department of Neurosurgery will be working closely together to bring this highly innovative research to our Health System.”
The Stentrode device, developed by Synchron, Inc., is a small brain-computer interface implanted through blood vessels in the brain. As part of the multi-site research effort, Mount Sinai will study how implantation of this device in six patients with severe paralysis, caused by stroke, injury, or late-stage amyotrophic lateral sclerosis (also known as Lou Gehrig’s disease, a neurodegenerative disease that causes severe paralysis of the entire body), can significantly improve quality of life, daily function, and ultimately health outcomes.
Neurointerventionalists implant the Stentrode using a catheter during a minimally invasive procedure. It goes through the jugular vein and into a large vessel near the primary motor cortex—the area of the brain that is responsible for producing movement commands. The Stentrode is the only brain-computer interface that can access the primary motor cortex with this approach, without requiring open brain surgery.
Although patients with paralysis are unable to voluntarily move their affected limbs, they still have the ability to produce brain signals in their motor cortex that can generate command functions. The Stentrode technology picks up those brain signals, then transmits them out of the brain to a small unit placed in the chest. The chest device is connected to an external receiver that converts the brain signals into commands and sends them wirelessly to a computer, allowing the patient to control it through thought. The patient can train their brain how to operate the computer and use it to communicate with family, caregivers, and friends, as well as perform other digital activities like shopping and banking.
Once the Stentrode is implanted, Dr. Putrino’s research team at the Abilities Research Center within Mount Sinai’s Department of Rehabilitation and Human Performance will work to evaluate the overall impact of this technology. They will assess the implant’s safety, and how effective it is in providing a quantifiable improvement in independence and quality of life for these patients.
The first implantation of the Stentrode technology in the United States is expected to take place within the next 12 months. Before that, researchers will perform imaging studies on healthy participants and those living with paralysis. This will help them understand what a neurotypical brain looks like from a vascular and functional perspective compared to those with paralysis. Researchers can then determine if participants with paralysis have the same capacity for supporting the brain implant in their blood vessel and producing usable brain signals as members of the general population. Having this information will allow them to create protocols for selecting patients for the study who will have good outcomes with implantation.
A recent publication in Journal of NeuroInterventional Surgery demonstrated that two Australian patients implanted with the Stentrode learned to control texting and typing through direct thought. After training on mouse-clicking, they used the system unsupervised in their homes to send text messages, shop online, and manage their finances.
“This technology can revolutionize how people with paralysis interact with the world—and the fact that it can be placed minimally invasively, without the need for open brain surgery, is simply amazing,” says Shahram Majidi, MD, Assistant Professor of Neurosurgery, Neurology, and Radiology at Icahn School of Medicine at Mount Sinai and Director of Cerebrovascular Services at Mount Sinai Brooklyn, who will be implanting the devices for Mount Sinai.
Carnegie Mellon University will lead this project, and University of Pittsburgh Medical Center has been named as the other research site to study Stentrode.
The project is funded by the National Institutes of Health Brain Research Through Advancing Innovative Neurotechnologies® (BRAIN) Initiative – (NS120191-01).
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving high "Honor Roll" status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s best in several pediatric specialties.